United Therapeutics has been closely monitoring the rapidly evolving situation around Coronavirus (COVID-19). We are dedicated to providing ongoing support for patients and healthcare providers, and ensuring an uninterrupted supply of drug product.

Resources

United Therapeutics is dedicated to providing resources to help support treatment with Remodulin. Below you’ll find important forms for Remodulin, patient resources, and informative videos to share with your patients.

Informative videos to share with your patients

Support Information

Specialty Pharmacies

Understand the advantages of focused support from Specialty Pharmacies.

SC Site Pain

Patients and healthcare professionals talk about site pain with Remodulin SC and ways to help manage it.

Doctors Dish: Pathways and Treatment Options

Dr. Stacy Mandras tells us how she determines which treatment may be right for her patients.

Patient Stories

Carey’s Story

Carey shares how she persevered and didn’t let her disease define her.

Donna’s Story—Remodulin (treprostinil) Injection IV

Donna discusses her obstacles with her disease, treatment with Remodulin IV, her daily routine, and how her experience inspired her to become a nurse.

Patient Documentary

Watch Errin and Donna discuss their experience with Remodulin IV and SC and the changes they’ve made since being diagnosed.

PAH Life Hacks

PAH Life Hacks: Showering With Your Pump

PAH patient Carey shares her tips on how to protect a pump in the shower.

PAH Life Hacks: Traveling With Your Pump

PAH patient Wendy shares some advice for traveling with a pump.

DAW=dispense as written; IV=intravenous; SC=subcutaneous.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).